Latest Oncology News

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

Kristi Rosa

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

June 29th 2022

Jason Harris

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

Kristi Rosa

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

Kristi Rosa

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

June 29th 2022

Chris Ryan

Socazolimab produced encouraging response rates with an acceptable safety profile in patients with recurrent or metastatic cervical cancer, irrespective of PD-L1 status, according to findings from the dose-expansion portion of a phase 1 trial.

Latest Oncology Videos

All Oncology News

NSCLC: Immunotherapy in Patients With Concomitant KRAS/TP53 Mutations

June 27th 2022

John Heymach, MD, PhD

Expert oncologist John Heymach, MD, PhD, addresses the potential role of immunotherapy in concomitant KRAS/TP53-mutated NSCLC.

TX05 Provides Comparable DFS Benefit to Trastuzumab in Early-Stage HER2+ Breast Cancer

June 27th 2022

Chris Ryan

Adjuvant treatment with TX05 resulted in a similar disease-free survival benefit to that of trastuzumab in patients with early-stage HER2-positive breast cancer.

Institutional Perspectives in Cancer- Lung: Chaired by Giuseppe Lo Russo, MD, PhD

June 27th 2022

Institutional Perspectives in Cancer- Lung: Chaired by Giuseppe Lo Russo, MD, PhD

I/O Therapy in KRAS-Mutant NSCLC With Concomitant STK11 or KEAP1 Mutations

June 27th 2022

John Heymach, MD, PhD

Insight on the potential role of immunotherapy in patients with NSCLC and concomitant KRAS/STK11 or KRAS/KEAP1 mutations.

Batiraxcept Combinations Under Further Investigation After Promising Efficacy Signals in Clear Cell RCC

June 26th 2022

Ryan Scott

Batiraxcept will continue to be investigated in combination with cabozantinib, plus in combination with cabozantinib and nivolumab and as a single agent, in patients with advanced or metastatic clear cell renal cell carcinoma in a phase 2 study.

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

June 25th 2022

Kristi Rosa

The combination of niraparib and dostarlimab produced a low overall response rate in patients with platinum-resistant ovarian cancer without a known BRCA mutation who had progressed and received prior bevacizumab, one that did not reach the threshold for second-stage accrual to the phase 2 MOONSTONE/GOG-3032 trial.

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

June 24th 2022

Caroline Seymour

The FDA has approved lisocabtagene maraleucel as second-line therapy for adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Dr. Lunning on the FDA Approval of Liso-cel in LBCL

June 24th 2022

Matthew A. Lunning, DO, FACP

Matthew A. Lunning, DO, FACP, discusses how the FDA approval of lisocabtagene maraleucel expands treatment options for patients with large B-cell lymphoma.

Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer

June 24th 2022

Antoinette R. Tan, MD, MHSc

Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.

Amivantamab/Lazertinib Combo Demonstrates Durable Activity in EGFR-Mutated NSCLC

June 24th 2022

Kristi Rosa

The combination of amivantamab-vmjw and lazertinib produced encouraging responses with acceptable safety in patients with EGFR-mutated non–small cell lung cancer who expressed on osimertinib and platinum-based chemotherapy.

Dr. Nakayama on the Current Treatment Landscape of Ovarian Cancer

June 24th 2022

John Nakayama, MD

John Nakayama, MD, discusses the current treatment landscape of ovarian cancer and where he hopes the field advances in the future.

Dr. Khorana on Rates of Young-Onset Pancreatobiliary Adenocarcinoma

June 24th 2022

Alok A. Khorana, MD

Alok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

June 24th 2022

Ryan Scott

Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

June 24th 2022

Kyle Doherty

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

Adjuvant Pembrolizumab Wins European Approval for Stage IIB/IIC Melanoma Following Complete Resection

June 24th 2022

Chris Ryan

The European Commission has approved pembrolizumab for adjuvant treatment of adult and adolescent patients 12 years and older with stage IIB or IIC melanoma who have undergone a complete resection.

See All News